Summit Therapeutics Bests Merck's Top Selling Drug In Phase III …
WEB1 day ago · Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. ... Since Summit's stock price depends on news flow rather than sales, this is a ...
Keytruda beaten by Summit’s bispecific in NSCLC - Yahoo Finance
WEB9 hours ago · SMMT. On 8 September 2024, Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific monoclonal antibody that binds to vascular ...
Here's Why Everyone's Talking About Summit Therapeutics
WEB3 days ago · Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock. ... the clinical-stage biotech's stock price was able to shoot more than 500% higher ...
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has ...
WEB2 days ago · Median progression free survival after nine months of follow-up was 11.14 months in the treatment arm vs. 5.82 months in the Keytruda group. Summit’s bispecific cut the risk of disease progression or death by nearly 50% compared to Keytruda. HARMONi-2 included a variety of patient subgroups, including …
Why Summit Therapeutics Rocketed Over 60% Today - Yahoo …
WEBSep 9, 2024 · Shares of Summit Therapeutics (NASDAQ: SMMT) rocketed as high as 75.2% Monday, before settling into a 57.5% gain as of 1:27 PM EDT. The biotech firm released the results of a Phase III study on ...
Press Releases - Summit Therapeutics
WEBFeb 20, 2024 · Summit Therapeutics Announces Timing of Rights Offering for Up to $500 Million. January 20, 2023. Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody. January 5, 2023. Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference.
Summit Therapeutics Reports Financial Results and Operational …
WEBMay 1, 2024 · Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024. HARMONi and HARMONi-3 Enrollment Continues. Promising Intracranial Anti-Tumor...
Summit Therapeutics’ stock pops as lung-cancer treatment beats …
WEBSep 9, 2024 · Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage trial data showing that its experimental lung-cancer treatment topped...
WCLC: Summit trumpets data with Keytruda challenger
WEBSep 9, 2024 · Summit Therapeutics and Akeso's ivonescimab tops Merck's Keytruda in head-to-head phase 3 trial in first-line NSCLC, reported at WCLC. ... Get in-depth news, opinions and features on pharma and ...
This Biotech’s Stock Has Quintupled Since May, Making Its Co
WEB11 hours ago · Shares of Nasdaq-listed Summit Therapeutics nearly doubled since September 6, lifting the company’s market capitalization to $17 billion. (Shares peaked at $31.93 on September 13 and dropped ...